Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Eli Lilly Corp.

Start price
Target price
Perf. (%)
€128.00
06.09.20
€125.00
04.11.21
-3.25%
06.11.20

Future proof or reliable business model
Higher risks for its business
Risky Investment
buy
Verastem Inc.

Start price
Target price
Perf. (%)
€11.94
06.09.20
€24.00
28.09.20
7.41%
28.09.20

Could be very worthwhile Investment >20% year
Fair valuation
Increased challenges to pay loans and raise capital
Risky balance sheet
buy
Novavax Inc.

Start price
Target price
Perf. (%)
€80.99
05.09.20
-
04.11.21
74.71%
03.06.21

Could be very worthwhile Investment >20% year
Cocrystal Pharma Inc.

Start price
Target price
Perf. (%)
€8.70
03.09.20
-
28.10.20
-0.69%
28.10.20

Could be very worthwhile Investment >20% year
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€2.19
03.09.20
-
03.09.20
-
03.09.20

High risks for its business
Ceapro Inc

Start price
Target price
Perf. (%)
€0.41
03.09.20
-
03.09.20
-
03.09.20

buy
PerkinElmer Inc.

Start price
Target price
Perf. (%)
€104.00
03.09.20
-
04.11.21
9.62%
05.11.20

Growths faster than the competition
Could be worthwhile Investment >10% per year
EBIT growth >5% per year expected
buy
Grifols S.A.

Start price
Target price
Perf. (%)
€22.77
01.09.20
€30.00
04.11.21
-18.75%
05.11.21

Could be worthwhile Investment >10% per year
buy
Uniqure B.V.

Start price
Target price
Perf. (%)
€32.45
29.08.20
€40.00
04.11.21
-7.18%
05.11.21

Could be worthwhile Investment >10% per year
buy
Stratec SE

Start price
Target price
Perf. (%)
€103.60
29.08.20
€120.00
31.08.20
-3.09%
31.08.20

Risky Investment
Stratec SE

Start price
Target price
Perf. (%)
€105.60
28.08.20
€95.00
04.11.21
5.30%
17.06.21

Probably not worthwhile Investment
Revenue decline/stagnation expected
High valuation
Very low/no dividend yield expected
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€55.32
26.08.20
€50.00
08.10.20
-2.68%
08.10.20

Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Teligent Inc.

Start price
Target price
Perf. (%)
€1.05
26.08.20
-
02.09.20
-13.71%
02.09.20

buy
Verastem Inc.

Start price
Target price
Perf. (%)
€13.13
25.08.20
€25.20
04.11.21
120.37%
05.11.21

Could be worthwhile Investment >10% per year
buy
Tonix Pharmaceuticals Holding Corp.

Start price
Target price
Perf. (%)
€145.00
25.08.20
-
04.11.21
-32.43%
05.11.21

Could be very worthwhile Investment >20% year
Pfizer Inc.

Start price
Target price
Perf. (%)
€30.93
25.08.20
€25.62
03.09.20
-2.45%
03.09.20

Capable Management
Good culture
Innovative
Differentiated customer and product portfolio
buy
Amgen Inc.

Start price
Target price
Perf. (%)
€207.40
25.08.20
€225.00
21.09.20
-1.23%
21.09.20

Could be worthwhile Investment >10% per year
High dividend yield expected
positive Cash Flow expected
Good rating
Seres Therapeutics Inc

Start price
Target price
Perf. (%)
€21.00
23.08.20
€12.00
04.11.21
-22.14%
17.06.21

Probably not worthwhile Investment
buy
Veracyte Inc.

Start price
Target price
Perf. (%)
€30.20
23.08.20
€45.00
04.11.21
49.01%
05.11.21

Could be worthwhile Investment >10% per year
Kazia Therapeutics ADR

Start price
Target price
Perf. (%)
€6.50
22.08.20
-
04.11.21
36.15%
17.06.21

Probably not worthwhile Investment
buy
Ceapro Inc

Start price
Target price
Perf. (%)
€0.59
22.08.20
-
03.09.20
-9.40%
03.09.20

buy
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€6.65
22.08.20
-
03.09.20
-11.28%
03.09.20

High risks for its business
buy
Motus GI Holdings Inc.

Start price
Target price
Perf. (%)
€16.70
22.08.20
-
04.11.21
-2.40%
03.06.21

Could be very worthwhile Investment >20% year
iBio Inc.

Start price
Target price
Perf. (%)
€36.75
22.08.20
-
04.11.21
-25.14%
15.07.21

Risky Investment
buy
Cocrystal Pharma Inc.

Start price
Target price
Perf. (%)
€14.64
22.08.20
-
03.09.20
-40.57%
03.09.20

Could be very worthwhile Investment >20% year